Patent US4604391A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4604391A Expired / Lapsed US ⏱️ 0.0 years remaining

Treatment of osteitis and osteomyelitis employing thiadiazine compounds

Assignee: Ed Geistlich Soehne AG fuer Chemische Industrie
•
Filing: 1984-10-19
•
Granted: 1986-08-05
•
Expires: 2004-10-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of formula (I) ##STR1## [wherein R 1 represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms and R 2 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or a group of formula (II) ##STR2## in which R 1 is as defined above] and pharmaceutical compositions thereof may be administered prophylactically to humans or warm-blooded animals to combat the occurrence of osteitis or osteomyelitis, especially in patients suffering from bone injuries of traumatic origin.

Inventors

  • 👤 Rolf W. Pfirrmann

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 12:19
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61P; A61P43/00; C; C07; C07D; C07D285/00; C07D285/15; C07D285/16; C07D285/18

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 91 words
A method of treating a human or warm-blooded animal patient suffering from bone injury to prevent the occurrence of osteitis or osteomyelitis, said method comprising administering systemically to said patient a therapeutically effective amount of a compound of formula (I) ##STR5## wherein R 1 represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms and R 2 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or a group of formula (II) ##STR6## in which R 1 is as defined above.
Claim 2
Independent Claim 91 words
A method of treating a human or warm-blooded animal patient suffering from bone injury to prevent the occurrence of osteitis or osteomyelitis, said method comprising administering systemically to said patient a therapeutically effective amount of a compound of formula (I) ##STR5## wherein R 1 represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms and R 2 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or a group of formula (II) ##STR6## in which R 1 is as defined above.
Claim 3
Dependent Claim 28 words
A method as claimed in claim 1 wherein there is administered to said patient a compound of formula (I) selected from the group consisting of taurolidine and taurultam.
Claim 4
Dependent Claim 19 words
A method as claimed in claim 1 wherein said compound of formula (I) is administered to said patient intravenously.
Claim 5
Dependent Claim 22 words
A method as claimed in claim 3 wherein from 10 to 40 g of said compound of formula (I) is administered daily.

References Cited (Backward Citations)

GB1124285A Cited
US4107305A Cited
US4337251A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-08-04 1990-02-03 1990-08-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-08-04 1994-02-03 1994-08-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-08-04 1998-02-03 1998-08-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag